Research analysts at Royal Bank Of Canada assumed coverage on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research note issued to investors on Thursday, The Fly reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on ABEO. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Friday, September 8th. Maxim Group set a $17.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 29th. BidaskClub upgraded Abeona Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 12th. Zacks Investment Research upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Tuesday, July 11th. Finally, Cantor Fitzgerald set a $21.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Abeona Therapeutics has an average rating of “Buy” and a consensus price target of $17.86.

Abeona Therapeutics (NASDAQ ABEO) traded up 0.536% during mid-day trading on Thursday, reaching $14.075. 616,754 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $9.74 and a 200-day moving average of $6.84. The stock’s market cap is $567.04 million. Abeona Therapeutics has a one year low of $4.05 and a one year high of $15.25.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.21 million. On average, equities research analysts anticipate that Abeona Therapeutics will post ($0.67) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Abeona Therapeutics Inc. (ABEO) Now Covered by Analysts at Royal Bank Of Canada” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/14/abeona-therapeutics-inc-abeo-now-covered-by-analysts-at-royal-bank-of-canada.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. State of Wisconsin Investment Board purchased a new position in shares of Abeona Therapeutics during the second quarter valued at approximately $122,000. Private Advisor Group LLC increased its stake in shares of Abeona Therapeutics by 50.0% during the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 6,999 shares during the period. Family Management Corp purchased a new position in shares of Abeona Therapeutics during the first quarter valued at approximately $120,000. Rhumbline Advisers purchased a new position in shares of Abeona Therapeutics during the second quarter valued at approximately $190,000. Finally, Segantii Capital Management Ltd increased its stake in shares of Abeona Therapeutics by 564.6% during the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 28,794 shares during the period. 38.24% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

The Fly

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.